Ocugen, Inc. is a biotechnology company developing gene therapies for inherited retinal diseases and blindness conditions. The company utilizes a modifier gene therapy platform to address unmet medical needs in ophthalmology. Its pipeline includes OCU400, a gene-agnostic therapy for retinitis pigmentosa, and OCU410ST, a treatment for Stargardt disease and ABCA4-associated retinopathies. Additionally, OCU410 is under development for geographic atrophy secondary to dry age-related macular degeneration. These therapies are designed to modulate lipid metabolism, oxidative stress, and inflammation to restore retinal homeostasis. Ocugen was co-founded in 2013 and is advancing clinical trials in the United States and Europe, with plans for regulatory submissions in the late 2020s.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ocugen.com
Sector Healthcare IR page ir.ocugen.com
Tags
gene therapy, retinal diseases, ophthalmology, modifier gene therapy, stargardt disease, retinitis pigmentosa, geographic atrophy, age-related macular degeneration, aav5 delivery, rare diseases, OCU400, OCU410ST, OCU410, RORA, AAV5, GARDian3, ArMaDa, liMeliGhT, GARDian1
Press page —

Metrics

Valuation  
Market cap $ 322.341M
Market cap (USD) $ 322.341M
P/E -4.75
PEG —
P/BV -18.23
P/S 73.04
P/OCF -5.66
P/FCF -5.64
Dividend yield —
Turnover / mcap —
Returns  
ROE 557.7%
ROI -408.1%
ROIC -283.8%
Profit margin -1,537.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score -68.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 4.413M 4.055M 6.036M 2.488M 0 42.62K — 0 0 0 0 0
Net profit -67.846M -54.054M -63.078M -81.351M -58.365M -21.822M -20.243M -8.643M -26.414M -16.208M -32.024M -22.793M
Free cash flow -57.149M -45.527M -72.53M -64.536M -48.88M -15.016M -16.923M -17.79M -23.296M -26.056M -31.983M -21.259M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 1.35 0.81 0.58 1.3 4.55 1.83 0.53 — — — — —
Price performance 12m 0.68 0.4 -0.56 -0.71 1.49 2.47 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 7.48M 0.00 234,119 0.00 0.00 0.00 1.33M 1.25M
Borrowings, non-current (USD) — — 1.02M 1.07M 1.82M 1.71M 2.29M 2.8M 27.3M 27.5M
Lease liabilities (USD) — — 54,162 335,508 433,565 1.59M 4.09M 4.14M 3.83M 4.35M
Cash and deposits (USD) 31.9M 7.08M 15.5M 7.44M 24M 95M 77.6M 39.5M 58.8M 18.9M
Right-of-use assets (USD) — — — 344,574 433,649 1.59M 3.91M 3.94M 3.61M 4.09M
Net debt (borrowings + leases - cash) (USD) — — 6.93M -6.04M -21.5M -91.7M -71.2M -32.5M -26.3M 14.3M
Cash flow detail
Operating cash flow (USD) -25.7M -23M -15.8M -16.9M -14.7M -47.9M -60.1M -62.1M -42.1M -57M
Purchases of property, plant and equipment (USD) -320,000 -276,000 -2.01M -29,446 -306,825 -939,000 -4.46M -10.5M -3.39M -185,000
Change in payables (cash effect) (USD) -435,000 -849,000 689,000 -1.63M -540,847 3.5M 9.49M -12.3M 4.14M 3.31M
Share buybacks (cash effect) (USD) — — 0.00 -47,864 0.00 0.00 — — — —
Interest paid (cash effect) (USD) -66,000 -30,000 -1,000 — — — — — — —
Income taxes paid (cash effect) (USD) -257,000 -197,000 -105,000 — — — — — — —
Share-based compensation (USD) 1.55M 1.57M 1.63M 884,089 660,317 6.96M 10.5M 9.22M 7.43M 7.71M
Free cash flow (OCF - PPE - intangibles) (USD) -26.1M -23.3M -17.8M -16.9M -15M -48.9M -64.5M -72.5M -45.5M -57.1M
Income detail
Research and development expense (USD) 21.6M 15.6M 15.6M 8.09M 6.35M 35.1M 49.8M 39.6M 32.1M 39.8M
↳ 5y CAGR +5.5% -20.7% -22.8% +10.2% +26.2% +20.4% +31.8% +44.3%
Total comprehensive income (USD) — — -18.2M -20.2M -21.8M -58.4M -81.3M -63.1M -54M -67.8M
Comprehensive income to owners (USD) — — -18.2M -20.2M -21.8M -58.4M -81.3M -63.1M -54M -67.8M
Reported Mar 16, 2017 Mar 15, 2018 Mar 27, 2020 Aug 14, 2020 Mar 19, 2021 Feb 28, 2022 May 5, 2023 May 14, 2024 Mar 5, 2025 Mar 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

· Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) markets

· Expands access to a potential one-time treatment gene therapy for RP across a region with an estimated 725 million people, following potential OCU400 approval in the U.S.

· Ocugen receives an upfront license fee, potential development and milestone payments totaling up to $7.1 million, including $6.1 million associated with the upfront payment and OCU400 top-line results (expected in the first quarter of 2027), a high single-digit percentage royalty on net sales, and 50% of gross profits from OCU400 net sales across the region

· Celairis will be responsible for regional regulatory submissions, market access, and commercialization of OCU400 across the region

MALVERN, Pa., and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and Celairis Therapeutics Holdings Pty Ltd.

Conference Call and Webcast Today at 8:30 a.m. ET

· Received Provisional Approval and Priority Designation for OCU400 in The Bahamas

o Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) to coordinate and manage patient care

o Progressing site readiness in preparation to accept patients

o Advancing toward full approval and potential patient enrollment as early as year-end

· Executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical

· Initiated dosing in Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA)

· Cash, cash equivalents, restricted cash, and short-term investments of $84.6 million as of September 30, 2026; with expected runway into 2028

MALVERN, Pa., November 4, 2026 -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update.

October 29, 2026

PDF Version

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in November 2026.

Stifel 2026 Healthcare Conference **Location:**New York, NY **Date:**Thursday, November 12, 2026 Time: 10:00–10:30 a.m. ET **Format:**Presentation **Presenter:**Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen

Cell & Gene Leaders Live 2026 **Location:**The Shard, London, UK **Date:**Sunday, November 15, 2026 Time: 3:15–4:00 p.m. GMT **Format:**Panel discussion **Presenter:**Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen

A webcast of the Stifel presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.

About Ocugen, Inc. Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Prompts

Ocugen, Inc. (ticker OCGN), listed in United States.

Company History

Date Change Detail
Oct 1, 2019 Renamed HISTOGENICS CORP → OCUGEN, INC.

ETFs Holding Ocugen, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.02% 388 $ 593.64 Jun 30, 2026